[Nle4, D-Phe7]-α-MSH, Afamelanotide (research context)
Evidence Grade C — Moderate human evidence. 19 published studies, 13 human. 0 registered clinical trials.
Melanotan I is the research name for the same molecule that is sold as the prescription medication Scenesse (afamelanotide) for a rare light-sensitivity condition. This entry covers its widespread unregulated use for cosmetic tanning — a purpose for which it has no approval. Products from unregulated sources are fundamentally different from the controlled pharmaceutical implant and lack quality assurance.
19 published studies: 13 human, 3 animal, 2 in-vitro, 8 reviews
Melanotan I is the same molecule as afamelanotide, which is approved as Scenesse (#42) exclusively for erythropoietic protoporphyria. It is not approved for cosmetic tanning or any other indication.
Melanotan I is widely available through unregulated channels for cosmetic tanning purposes. This use is not supported by regulatory approval, and the safety of chronic self-administration for cosmetic purposes has not been established through clinical trials. Products from unregulated sources lack pharmaceutical quality assurance. The approved product (Scenesse) is administered under medical supervision as a controlled-release subcutaneous implant — a fundamentally different delivery method from unregulated injectable products.
Melanotan I activates the MC1R melanocortin receptor on melanocytes, stimulating eumelanin production (the photoprotective brown-black pigment). This is the same mechanism by which the approved formulation (Scenesse) provides photoprotection in EPP. The mechanism is well established from both preclinical research and the approved product's regulatory dossier.
Research suggests the prescription version (Scenesse) has a solid evidence base for the rare condition EPP, with clinical trials showing meaningful improvements in light tolerance. Long-term melanoma risk monitoring spanning over 10 years has shown no signal to date. However, the unregulated use for cosmetic tanning is a completely different context. No clinical trials have established the safety of chronic self-administration for cosmetic purposes. The pharmaceutical product is a controlled-release subcutaneous implant given under medical supervision — unregulated injectable products offer none of these safeguards. Products from unregulated sources lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
Epitalon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. Animal lifespan studies in mice reported by the Khavinson group form the core evidence base. The telomerase activation claims are based on in vitro studies and mouse models from a single research programme. Independent replication of the key findings has not been published. The relationship between in vitro telomerase activation and any clinical outcome in humans is not established. Products available through unregulated channels lack pharmaceutical quality assurance.
FOXO4-DRI has no marketing authorisation. No human clinical trials have been conducted. The evidence comes from a single high-profile publication (Cell, 2017) demonstrating effects in three mouse models. The senolytic field is an active area of pharmaceutical research, but FOXO4-DRI faces significant challenges for clinical translation, including its large size (46 amino acids), manufacturing complexity, and the absence of human pharmacokinetic or safety data. Products available through unregulated channels — which would need to reliably synthesise a 46-amino-acid all-D-amino-acid peptide — face exceptional quality assurance challenges.
